TORONTO, Aug. 19 /CNW/ - Biosign Technologies Inc. (CNSX: BIO) ("Biosign" or the "Company") today announces ALQAEM International (FZE), exclusive master distributor for the Middle East and North Africa Region (M.E.N.A.) has placed an initial order of 2000 Biosign UFIT(R) Ten-20 devices.
This initial order is required to meet greater than expected demand in several countries in the M.E.N.A. region for the Biosign Health Monitoring Solution and ALQAEM's successful closing of its first Egyptian reseller. Under the terms of the Exclusive Master Distribution Agreement announced July 7th, 2010, ALQAEM is expected to order in excess of 14,000 units by the end of 2011.
John Rizvi, Managing Director of ALQAEM stated: "Countries in the Middle East and North Africa region are increasingly turning to technology in fighting obesity, hypertension and type-2 diabetes. In August of this year, the Saudi government announced $6 billion is budgeted for eHealth spending in 2010 alone to help take on this challenge. UFIT(R) products have great potential to improve health outcomes in M.E.N.A. and integrate into eHealth programs in this region. We anticipate an enthusiastic response to the Biosign UFIT(R) non-invasive solution in all M.E.N.A. countries"
UFIT(R) TEN-20 is an online medical device for self-monitoring of blood pressure and blood glucose. The device takes the pulse at the wrist through an inflatable cuff and immediately produces blood pressure and blood glucose measurement results. All measurements are indirect, noninvasive, and passive. The results are stored on Biosign servers along with the test sample. Readings can be viewed by care providers on a secure web portal and/or integrated into a patient's Electronic Health Record (EHR). The UFIT(R) TEN-20 is approved under ISO 13485 for the non-invasive measurement of blood pressure and blood glucose, and carries the CE Mark.
ALQAEM International (FZE) is a diversified trading and distribution company headquartered in Sharjah, United Arab Emirates. A large potion of ALQAEM's business is health-care focused, and the company has supplied a number of high-tech product lines to hospitals in Dubai, Abu Dhabi and the other United Arab Emirates. In addition, Alqaem directs healthcare sales teams in a number of Gulf countries. In July 2010 ALQAEM was appointed the exclusive Master Distributor for Biosign health monitoring products for 10 countries in the M.E.N.A region.
About Biosign Technologies Inc.
Biosign Technologies Inc. (CNSX: BIO) provides biomedical and intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose and medication. The core technology combines measurement, analysis and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.
The CNSX has neither approved nor disapproved the contents of this press release.
SOURCE Biosign Technologies Inc.
For further information: For further information: John Anders, Vice-President, Business Development, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 237, Email: firstname.lastname@example.org